solute carrier family 6 member 13Genealiases: GAT-2 · GAT2 · GAT3
Q-omics provides the consensus-scored SLC6A13 profile across patient tissues and cancer cell-line models. SLC6A13 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC6A13 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, SLC6A13 protein abundance shows 16,045 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, KICH, and LSCC as cancer lineages where SLC6A13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC6A13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC6A13 survival associations across molecular data types. SLC6A13 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC6A13 RNA expression–survival associations across cancer types. High SLC6A13 expression shows unfavorable associations in UCEC and LUAD, but favorable associations in KIRC, KIRP, UCS and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC6A13 RNA expression.
This table summarizes SLC6A13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC6A13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC6A13 shows lower tumor expression in KICH, LUAD, THCA, LUSC and CHOL and higher tumor expression in KIRC. The KICH box plot shows higher SLC6A13 RNA expression in normal versus tumor tissue (log2 FC = −4.732, t-test p < 0.001).
This table shows molecular features associated with SLC6A13 in patient tissues and cancer cell lines. In patient samples, SLC6A13 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC6A13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Lymphoma.
